BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Beyer AP, Moise PA, Wong M, Gao W, Xiang C, Shen P, Pavlakis M, Vincenti F, Wang W. Clinical events and healthcare resource utilization associated with neutropenia and leukopenia among adult kidney transplant recipients receiving valganciclovir. World J Transplant 2025; 15(2): 102671 [PMID: 40535505 DOI: 10.5500/wjt.v15.i2.102671]
URL: https://www.wjgnet.com/2220-3230/full/v15/i2/102671.htm
Number Citing Articles
1
Muhammad Usman, Zhihan Yuan, Hao Yu, Xutao Chen, Zhuang Tang, Cheng Liu, Zhouhang Li, Wang He, Kewei Xu. Beyond valganciclovir: A meta-analysis of letermovir’s safety and efficacy in cytomegalovirus prophylaxis after solid organ transplantationBMC Infectious Diseases 2026; 26(1) doi: 10.1186/s12879-026-13022-1
2
David J. Taber, Hannah Culpepper, Courtney E. Harris, Neha Patel, Morgan Overstreet, Felicia Bartlett, Sakshi Vaishnav, Maria Aurora Posadas Salas, Santosh Nagaraju, Steve Hanish. Single-Center, Open-Label, Randomized Controlled Trial Comparing the Tolerability of Maribavir 400mg Twice Daily versus Standard Dose Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant RecipientsAmerican Journal of Transplantation 2026;  doi: 10.1016/j.ajt.2026.05.729